organization · Reporting owner
Janus Henderson Group Ltd.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ABIO · Entity 3781 | 10% owner | August 16, 2024 | August 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date August 16, 2024 · Filed August 20, 2024
Jointly reported with Janus Henderson Biotech Innovation Master Fund Ltd
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 2,117,213 |
Last balance in matching sequence
After 2024-08-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-08-16 · Purchase · Acquired 5,390 · Balance 2,116,785 F1: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Row 2 · 2024-08-16 · Purchase · Acquired 428 · Balance 2,117,213 F1: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2024 Filed Aug 20, 2024 18:23 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 428 | $2.98 | $1,274.07 |
DisclosureSEC source: 0001437749-24-027344 · rdgdoc.xml · nonDerivative · entry 2 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 2,117,213 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 18:23 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 5,390 | $2.93 | $15,792.70 |
DisclosureSEC source: 0001437749-24-027344 · rdgdoc.xml · nonDerivative · entry 1 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 2,116,785 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 14:50 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 30,227 | $3.05 | $92,292.10 |
DisclosureSEC source: 0001437749-24-023533 · rdgdoc.xml · nonDerivative · entry 4 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 2,111,395 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 14:50 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 7,056 | $3.16 | $22,277.91 |
DisclosureSEC source: 0001437749-24-023533 · rdgdoc.xml · nonDerivative · entry 3 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 2,081,168 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 14:50 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 17,800 | $3.18 | $56,595.10 |
DisclosureSEC source: 0001437749-24-023533 · rdgdoc.xml · nonDerivative · entry 2 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 2,074,112 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 14:50 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 165,000 | $3.20 | $528,000.00 |
DisclosureSEC source: 0001437749-24-023533 · rdgdoc.xml · nonDerivative · entry 1 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 2,056,312 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 11, 2024 Filed Jul 12, 2024 23:38 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 94,537 | $3.45 | $326,303.91 |
DisclosureSEC source: 0001437749-24-022708 · rdgdoc.xml · nonDerivative · entry 9 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 1,891,312 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 23:38 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 21,963 | $3.46 | $76,062.26 |
DisclosureSEC source: 0001437749-24-022708 · rdgdoc.xml · nonDerivative · entry 8 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 1,796,775 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 23:38 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 33,500 | $3.46 | $116,067.45 |
DisclosureSEC source: 0001437749-24-022708 · rdgdoc.xml · nonDerivative · entry 7 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 1,774,812 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 09, 2024 Filed Jul 12, 2024 23:38 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 16,917 | $3.43 | $58,091.29 |
DisclosureSEC source: 0001437749-24-022708 · rdgdoc.xml · nonDerivative · entry 6 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 1,741,312 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 08, 2024 Filed Jul 12, 2024 23:38 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 17,600 | $3.54 | $62,216.00 |
DisclosureSEC source: 0001437749-24-022708 · rdgdoc.xml · nonDerivative · entry 5 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 1,724,395 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 08, 2024 Filed Jul 12, 2024 23:38 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 29,892 | $3.41 | $101,973.57 |
DisclosureSEC source: 0001437749-24-022708 · rdgdoc.xml · nonDerivative · entry 4 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 1,706,795 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 05, 2024 Filed Jul 12, 2024 23:38 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 5,000 | $3.41 | $17,050.00 |
DisclosureSEC source: 0001437749-24-022708 · rdgdoc.xml · nonDerivative · entry 3 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 1,676,903 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 05, 2024 Filed Jul 12, 2024 23:38 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 23,326 | $3.43 | $80,015.18 |
DisclosureSEC source: 0001437749-24-022708 · rdgdoc.xml · nonDerivative · entry 2 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 1,671,903 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 03, 2024 Filed Jul 12, 2024 23:38 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 166,042 | $3.55 | $589,565.33 |
DisclosureSEC source: 0001437749-24-022708 · rdgdoc.xml · nonDerivative · entry 1 JANUS HENDERSON GROUP PLC · CIK 0001274173 · 10% owner Janus Henderson Biotech Innovation Master Fund Ltd · CIK 0002030299 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fund Disclosed balance after: 1,648,577 F1 · ownership.nature: The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.